Tagged with IP,

Mexico The United States Trade Representative Office has been engaging with a number of countries, including Mexico, to address concerns related to IP protection and enforcement and market access barriers for pharmaceuticals and medical devices. Mexico remained on USTR’s Watch List in 2019 because there has not been a significant change…

USA Matt Eyles, president and CEO of the Association of Healthcare Insurance Providers (AHIP) outlines how the US health insurance landscape has evolved in the last ten years, counters some of the pharmaceutical industry’s criticisms of insurance firms, and outlines why greater affordability of healthcare in the US will benefit all…

Saudi Arabia Saudi Arabia is aiming to become a more attractive investment destination for multinational pharma companies through economic development projects that facilitate ease of doing business. Not stopping there, the Kingdom has a bold ambition to become a pharma hub for the entire Middle East region.    Saudi Arabia has the…

UAE PharmaBoardroom highlights three pharma executives whose experience in the Middle East has served to propel them into global leadership positions.   The Middle East and North Africa region is comprised of 22 countries and has a population of nearly 400 million. The region is home to a fast-growing pharma market…

Egypt As Egypt rolls out Universal Health Insurance with the aim of achieving full coverage between 2030 and 2035, the domestic pharmaceutical market stands to see significant long-term shifts. As self-medication is currently the cheapest form of treatment, out-of-pocket expenditures make up 62 percent of total health expenditure; a number which…

China The Greater Bay Area’s – and in particular, Shenzhen’s – prowess in life sciences manufacturing and development must also be attributed to the decades of experience and expertise gained from acting as OEM/ODM to global companies, in line with China’s overall positioning as the world’s factory floor. One of the…

Algeria With non WTO members such as Algeria flouting intellectual property (IP) it raises the issue of how best to protect and price medicines in the future. In a fascinating interview we spoke to Rachid Kerrar from the Algerian firm Beker about their development of a cheaper, generic version of Gilead’s…

Diversity Ai Hua Ong, Company Group Chairman, Asia Pacific, The Janssen Pharmaceutical Companies of Johnson & Johnson.   There is a clear correlation between an inclusive culture and innovation Creating a diverse workforce and an inclusive culture is key to an organisation’s success in today’s and tomorrow’s world. Organisations large and…

UK With four out of the five NHS bodies, Leeds City Region is strongly anchored in the British life sciences ecosystem. Chair of Leeds City Region Enterprise Partnership, Roger Marsh OBE, highlights what else makes the region special: its great talent, dedication to discovery and ability to build bridges between academia…

Portugal Oscar Gaspar, VP of the Confederation of Portuguese Industry (CIP), president of the Portuguese Association of Private Hospitalization and former secretary of state for health (2009-2011), provides an informative insight into the state of Portugal’s healthcare system. Through compelling suggestions and observations on the current system, Gaspar sheds light on…

Tunisia Ridha Charfeddine, founding CEO of Unimed and president of the National Chamber of the Pharmaceutical Industry (CNIP) discusses enforcing European quality standards in Tunisia, the CNIP’s role in guiding pharmaceutical and medical device companies in Tunisia, as well as his entrepreneurial journey with Unimed, now the preferred partner of the…

Mexico Sergio Olivares, managing director at Olivares, explains the TPP’s impact on the Mexican pharmaceutical industry’s dynamism and Olivares’ business proposal as a one-stop shop solution to fulfill all its current and future clients’ intellectual property needs. Olivares began as an intellectual property (IP) boutique in 1969 and is today the…